Fast-Acting Insulin Called a Suitable and Cost-Efficient Alternative for Treating Ketoacidosis


By: Daniel Trecroci

For kids suffering from diabeticketoacidosis (DKA), researcherssuggest an alternative treatment: thefast-acting insulin Humalog.

In a study that took place betweenJune 2001 and June 2003, 60episodes of DKA with a bloodglucose level of 300 mg/dl wererecorded. Of the 60 episodes, 30were treated every two hours with0.15 units per kilogram (translate tounits) of Humalog. The other 30 casesreceived continuous intravenousRegular insulin (CIRI).

Respectively, capillary glucose levelsdecreased by 252.2 mg/dl and 46.8mg/dl in the Humalog and CIRIgroups, prompting the researchersto conclude that DKA treatment witha subcutaneous fast-acting insulinanalog represents a “cost-effectiveand technically simplified procedurethat precludes intensive care unitadmission.”

—Diabetes Care, August 2004



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.